In July 2023, after receiving post-marketing reports of SI/B in patients taking GLP-1RA medications, the FDA initiated an investigation into whether there is an established link between the drugs and the psychiatric adverse events
Your body's metabolic set point also plays a role
This is why retention not just efficacy is the real problem to solve
Kennedy Jr., want the government to ease restrictions to make them more accessible and to discourage people from purchasing them elsewhere online
PubMed, 2024 Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults British Journal of Pharmacology, 2025 Consuming more protein may protect patients taking an anti-obesity drug from muscle loss Endocrine Society, ENDO 2025 Preserving Lean Body Mass in Patients Taking GLP-1 for Weight Loss Mass General Advances in Motion GLP-1s and Lean Mass: What the Research Shows ACE Certified, June 2025 New GLP-1 Therapies Enhance Quality of Weight Loss by Improving Muscle Preservation American Diabetes Association, 2025 Impact of GLP-1 Receptor Agonist Therapy in Patients at High Risk for Sarcopenia Current Nutrition Reports, Springer, 2025
